title: Does adenosine deaminase inhibition protect ischemic myocardium?
authors.affiliation: Parke-Davis Pharmaceutical Division, Warner Lambert Co., Ann Arbor, MI 48105, USA.
authors.forename: K P
authors.initials: KP
authors.lastname: Gallagher
authors.forename: T B
authors.initials: TB
authors.lastname: McClanahan
authors.forename: B J
authors.initials: BJ
authors.lastname: Martin
authors.forename: L J
authors.initials: LJ
authors.lastname: Saganek
authors.forename: D P
authors.initials: DP
authors.lastname: Ignasiak
authors.forename: T E
authors.initials: TE
authors.lastname: Mertz
authors.forename: D G
authors.initials: DG
authors.lastname: Van Wylen
authors.forename: J
authors.initials: J
authors.lastname: Vinten-Johansen
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives / Q000494:pharmacology; D058892:Adenosine Deaminase Inhibitors; D000818:Animals; D004791:Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D066298:In Vitro Techniques; D017202:Myocardial Ischemia / Q000188:drug therapy / Q000503:physiopathology*; D015649:Pentostatin / Q000494:pharmacology / Q000627:therapeutic use; D011817:Rabbits
chemical_list: D058892:Adenosine Deaminase Inhibitors; D004791:Enzyme Inhibitors; D015649:Pentostatin; C010192:9-(2-hydroxy-3-nonyl)adenine; D000225:Adenine